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Abstract
NAFLD is the most common liver disease worldwide but it is the potential evolution to NASH and eventually to
hepatocellular carcinoma (HCC), even in the absence of cirrhosis, that makes NAFLD of such clinical importance. Aim: we
aimed to create a mouse model reproducing the pathological spectrum of NAFLD and to investigate the role of possible co-
factors in promoting HCC. Methods: mice were treated with a choline-deficient L-amino-acid-defined-diet (CDAA) or its
control (CSAA diet) and subjected to a low-dose i.p. injection of CCl4 or vehicle. Insulin resistance was measured by the
euglycemic-hyperinsulinemic clamp method. Steatosis, fibrosis and HCC were evaluated by histological and molecular
analysis. Results: CDAA-treated mice showed peripheral insulin resistance at 1 month. At 1–3 months, extensive steatosis
and fibrosis were observed in CDAA and CDAA+CCl4 groups. At 6 months, equal increase in steatosis and fibrosis was
observed between the two groups, together with the appearance of tumor. At 9 months of treatment, the 100% of CDAA+
CCl4 treated mice revealed tumor versus 40% of CDAA mice. Insulin-like Growth Factor-2 (IGF-2) and Osteopontin (SPP-1)
were increased in CDAA mice versus CSAA. Furthermore, Immunostaining for p-AKT, p-c-Myc and Glypican-3 revealed
increased positivity in the tumors. Conclusions: the CDAA model promotes the development of HCC from NAFLD-NASH in
the presence of insulin resistance but in the absence of cirrhosis. Since this condition is increasingly recognized in humans,
our study provides a model that may help understanding mechanisms of carcinogenesis in NAFLD.
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Background
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related death worldwide. [1,2]. Moreover, several
studies have shown that 5% to 30% of patients with HCC lack a
readily identifiable risk factor for their cancer [1]. Most of these
‘‘cryptogenic’’ HCC might be attributed to Non-Alcoholic Fatty
Liver Disease (NAFLD) and the concomitant metabolic syndrome
[2,3], nevertheless it is not yet clear what predisposes to the
progression of the disease [4].
On this regard, NAFLD is a major health problem that
integrates several liver conditions ranging from simple fatty liver to
Non-Alcoholic Steatohepatitis (NASH), which is associated with
fibrosis that may evolve into cirrhosis and results into HCC [5].
How HCC develops from NASH livers is still obscure. Some
hypotheses suggest that obesity, insulin resistance, release of
inflammatory cytokines and autophagy can contribute to the
carcinogenic potential in NASH liver, where HCC can occur in
65% of patients without an over cirrhosis in the background liver
[6]. However, no direct link has been provided yet. Studies that
aim to link HCC and NAFLD are blunted by the lack of reliable
animal models. The use of a choline-deficient L-aminoacid-
defined diet (CDAA) in rats provided the most interesting results
inducing steatohepatitis [7]. Concerning this issue, a still
unresolved question is however related to the potential of CDAA
diet in inducing insulin resistance [8,9]. The purpose of this study
is to develop a mouse model of liver injury which mimics NASH
features that lead to HCC.
Materials and Methods
Animals and Treatment
Male 6 to 8 weeks old C57BL/6 mice were purchased from
Charles River Laboratories International, Inc. (Wilmington, MA).
Animals were fed a CDAA diet or its control diet, CSAA diet
(Laboratorio Dottori Piccioni, Milano, Italy). In parallel experi-
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ments, starting simultaneously to the diet administration, liver
fibrosis was enhanced by weekly intraperitoneal injections of
Carbon Tetrachloride (CCl4) at the dose of 0.2 ml/g of body
weight. Mice (8 mice/group) were sacrificed at 1, 3, 6 and 9
months of treatment and samples processed for histopathology,
serological and molecular analysis.
All animal work has been conducted according to the local
committee for care and use of laboratory animals. The study
protocol was approved by the Ethical Committee for animal
experimentations of the ‘‘Universita` Politecnica delle Marche’’
under the protocol named FIRB07/2011GE.
Evaluation of Peripheral Insulin Resistance
After 1 month of treatment, we evaluated peripheral insulin
resistance by the euglycemic-hyperinsulinemic clamp method [10].
Surgery for the positioning of catheters was performed 3 to 5 days
prior to the insulin clamp procedure as previously described [11].
The euglycemic-hyperinsulinemic clamp was performed in the
awake unrestrained state after 6 hour-fast. At time 0, a primed
continuous (4.0 mU/kg/min, Actrapid 100U, Novo Nordisk,
Copenhagen, Denmark) infusion of human insulin was started
simultaneously with a variable infusion of 10% dextrose in order to
maintain the plasma glucose concentration constant at its basal
level (80–100 mg/dl). Fasting Plasma Glucose (FPG) was mea-
sured at time 0. Subsequently, blood samples were taken from the
tail vein at 10 min intervals for at least 2 hours to measure glucose
concentration and adjust dextrose infusion rates. Insulin sensitivity
was calculated as M value (rate of peripheral glucose uptake) from
average glucose concentrations and dextrose infusion rates during
the last 30 min of the steady-state clamp period. Fasting insulin
concentrations were measured using an ELISA kit (Merck
Millipore, Darmstadt, Germany).
Triglyceride Measurement
Hepatic triglyceride content was measured as previously
reported [12].
Liver Histology and Immunohistochemistry
Mice liver tissues were fixed in 10% buffered formalin and
embedded in paraffin. Liver sections were routinely stained
Hematoxylin and Eosin and Sirius Red. Frozen sections from
the different groups of mice were stained for Oil Red O. Diagnosis
of NASH was based on the presence of steatosis, inflammation and
hepatocyte ballooning. The severity was assessed by using the NAS
scoring system [13].
For Immunohistochemistry, liver sections were incubated with
primary monoclonal antibodies against Alpha-Smooth Muscle
Actin (aSMA) (DakoCytomation, Carpinteria, CA), p-AKT
Ser473, b-Catenin (Cell Signaling, Boston, MA), p-c-Myc
Ser373 (Biorbyt, Cambridge, UK) and Glypican-3 (Cell Marque,
Rocklin, CA). Antibodies against Ki67 and F4/80 were from
ABCAM, Cambridge, UK. In Situ Cell Death (TUNEL) kit was
from Roche, Manneheim, Germany. Detection of positive staining
was performed by using DAB reagent (Sigma-Aldrich, St. Louis,
MO).
Quantitative morphometry was performed as previously
described [14,15].
Quantitative Real-time Reverse Transcription-Polymerase
Chain Reaction (qRT-PCR)
Total RNA was extracted from mice liver using TRIzol
Reagent (Life Technologies Corporation, Woburn, MA). Total
RNA was reverse-transcribed to complementary DNA [14]. qRT-
PCR was performed using Rotor-Gene 6000 instrument (Corbett
Life Science Pty. Ltd., Mortlake, NSW, Australia). The relative
abundance of the target genes was normalized to 18S rRNA as
internal control.
Statistical Methods
Results are expressed as mean 6 SEM. The results were
analyzed using ANOVA test. A p value of less than 0.05 was
considered statistically significant.
Results
Treatment with CDAA Induces Insulin Resistance
We evaluated the effects of CSAA and CDAA diets with the
association of CCl4 on peripheral insulin resistance by the
euglycemic-hyperinsulinemic clamp method. After 1 month of
treatment, mice treated with CDAA diet develop peripheral
insulin resistance as shown higher fasting plasma insulin concen-
trations (Fig. 1C) and the lower glucose uptake in comparison to
CSAA-treated mice (M value, Fig. 1B), despite a similar level of
FPG between the two diets evaluated at time 0 (Fig. 1A).
Conversely, CCl4 treatment induces a significant increase in FPG
levels and potentiates the lowering of peripheral glucose uptake
both in CSAA and CDAA diets (Fig. 1A–B). The above mentioned
experiments were performed by infusing insulin at a very high
rate, which is associated to a complete suppression of hepatic
glucose production. Insulin levels increased in animals treated with
CDAA (Fig. 1C).
Moreover, both CSAA and CDAA diets lead to a progressive
and time-dependent increase in body weight (Fig. 1D). This was
associated to a constant amount of caloric intake that did not differ
between CSAA- and CDAA-treated animals at all time points, not
significantly affected by CCl4 administration (data not shown).
Furthermore, mice treated with a concomitant chronic low-dose
injection of CCl4 show a significant reduction in body weight in
comparison to not injected-mice (Fig. 1D).
The epididymal fat/body weight ratio strongly confirms the
previous results (Fig. 1E), showing a significant increase from 3 to 9
months with both diets, with similar reduction in the presence of
CCl4.
Treatment with CDAA Determines a Progressive Increase
of Hepatic Steatosis
CDAA diet-treated mice show an increase in liver/body weight
ratio (Fig. 2A), compared to CSAA diet, starting already at 1
month. No significant differences are observed in association to
CCl4.
Oil Red O staining in mice treated with CDAA shows
significantly higher lipid deposition in comparison to mice treated
with CSAA as can be observed in the representative pictures at 3
months treatment and quantified by the morphometric analysis for
each time point (Fig. 2B). Furthermore, hepatic triglyceride
content is increased in CDAA- and CDAA+CCl4-treated animals
but not in its control diet alone or together with CCl4 (Fig. 2C).
Gene Expression Modifications of Enzymes of
Carbohydrate and Lipid Metabolism
Hepatic steatosis was associated to specific modifications in gene
expression of elements involved in carbohydrate and lipid
metabolism (Figure 3). The expression of enzymes associated with
gluconeogenesis, as Phosphoenolpyruvate Carboxykinase
(PEPCK) and glucose production, as Glucose 6-phosphatase
(G6PC) was reduced in the liver of CDAA-treated animals starting
HCC and NASH
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at 1 months, and further decreased at 9 months, independently
from CCl4 administration indicating that hepatic insulin resistance
was not increased by CDAA (Fig. 3A–B).
On the other hand, the hepatic expression of the Sterol
Regulatory Element Binding Protein-1c (SREBP-1c), that is the
transcription factor activating all genes required for lipogenesis
[16], was slightly reduced by CDAA treatment without major
modifications induced by CCl4 administration in our experimental
model (Fig. 3C). Furthermore, the Carbohydrate-Responsive
Element-Binding Protein (ChREBP), a key element of glucose-
mediated stimulation of lipogenesis [16] progressively decreased in
CDAA-treated animals, independently from CCl4 administration,
starting at 1 month (Fig. 3D). These data indicate that the
development of steatosis in CDAA model was not associated with
an increased lipogenesis.
Thus, we analyzed the pathways related to FA oxidation,
finding a decreased expression of both ACOX-1 (a rate-limiting
enzyme in peroxisomal fatty acids b-oxidation) and CPT1A (a key
enzyme in mitochondrial fatty acids b-oxidation) [12] observed in
CDAA+CCl4-treated animals at 1 months and in CDAA mice
thereafter, indicates that reduced fatty acid oxidation could be one
of the mechanisms of hepatic steatosis (Fig. 3E–F).
Figure 1. Effect of diet treatment on metabolic parameters and body weight. A–B) Mice treated with CDAA diet for 1 month develop
peripheral insulin resistance as shown by the lower glucose uptake vs CSAA-treated mice (M value) with similar levels of FPG. CCl4 treatment induces
an increase in fasting plasma glucose and enhances the condition of insulin resistance, reducing M value. C) Insulin levels measured at 1 month of
treatment. D) The graphic shows a gradual increase in body weight in both CDAA and CSAA diet. CCl4 injection similarly reduces body weight in both
diets. E) Epididymal fat/body weight ratio appears to be similar between the two different diets both at 3 and 9 months of treatment, with similar
reduction in the presence of CCl4. Data represent mean 6 SD; 1p,0.05 vs CSAA; u` p,0.05 vs CDAA; *p,0.05 vs CSAA 3 months;#p,0.05 vs CSAA+
CCl4 3 months; o` p,0.05 vs CDAA 3 months; c¸ p,0.05 vs CDAA+CCl4 3 months; b p,0.05 vs CSAA+CCl4 6 months; c p,0.05 vs CSAA+CCl4 9 months;
d p,0.05 vs CSAA.
doi:10.1371/journal.pone.0097136.g001
HCC and NASH
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Treatment with CDAA or CDAA+CCL4 Induces Liver
Damage and Hepatic Fibrosis in Mice
The effect of CDAA diet in terms of liver injury and fibrosis was
analyzed at the level of both gene expression and histological
analysis for different aspects of liver injury, inflammation, and
fibrosis (Fig. 4–6).
Concerning inflammation, at the histological level, by Immu-
nohistochemistry, the pan-macrophage marker F4/80 increased at
all time points tested, reaching the highest level in CDAA+CCl4-
treated animals at 3 months (Fig. 4A). In addition, CDAA feeding
increases at early stage the expression of genes related to liver
injury and inflammation, such as the Tumor Necrosis Factor
Alpha (TNFa) (Fig. 4B), the Monocyte Chemotactic Protein-1
(MCP-1) (Fig. 4C) and the Inflammasome components as the
Apoptosis-associated Speck-like protein containing a CARD
(ASC), Caspase-1 and Interleukin-1 beta (IL-1b) (Fig. 4D–F).
After blind evaluation by an expert liver pathologist (M.G.),
treatment with CSAA+CCl4 induces different degrees of hepato-
cyte necrosis and lobular inflammation. A more severe degree of
steatosis and necrosis is observed at histology in mice treated with
CDAA+CCl4. The CDAA+CCl4 treatment, already at 3 months,
is able to create a condition that resembles the human NASH with
a NAS score .5 (Fig. 5A). This was associated to a light but
significant increase in the number of apoptotic cells as measured
by TUNEL staining (Fig. 5B). We further investigated the
expression of fibrogenic markers at each time point. CDAA+
CCl4 treatment induced a stable and significant increase of the
Metallopeptidase Inhibitor-1 (TIMP-1) (Fig. 5C) and cytokines
involved in collagen synthesis stimulation such as the Connective
Tissue Growth Factor (CTGF) and the Transforming Growth
Factor b (TGFb) starting at 3 months (Fig. 5D–E). Notably,
CDAA+CCl4 treatment shows the higher increase in mRNA
expression of Collagen a1(I) in a time-dependent manner (Fig. 6A).
Additionally, qRT-PCR analysis shows in the CDAA+CCl4 group
a time-dependent increase of mRNA levels of aSMA, a marker of
Hepatic Stellate Cell (HSC) activation and fibrogenesis, reaching
the highest levels at 9 months of treatment (Fig. 6B). The CDAA
diet alone is also able to induce fibrogenesis, but the increase is
significantly lower than in the CDAA+CCl4 group. Conversely,
the CSAA diet determined a modest increase in fibrogenesis only
in the presence of CCl4 (Fig. 6A–B).
Similar results were obtained from the morphometric analysis of
the Sirius Red-positive parenchyma that reveals at 6 months the
Figure 2. Treatment with CDAA determines a progressive increase of hepatic steatosis. A) Increased levels of liver/body weight fraction
are observed in the group of mice treated with CDAA diet, either with or without CCl4 administration, in comparison to mice treated with control
diet, starting at 1 month. B) Histochemical staining and relative morphometric evaluation for Oil Red O and C) hepatic triglyceride measurement show
increased deposition of lipids in the liver parenchyma of CDAA and CDAA+CCl4 treated animals in comparison to CSAA treated mice. Data represent
mean 6 SD; o` p,0.05 vs CSAA 1 month; *p,0.05 vs CSAA 3 months; 1p,0.05 vs CSAA 6 months; #p,0.05 vs CSAA 9 months; c¸ p,0.05 vs CDAA 6
months; u` p,0.05 vs CDAA 9 months.
doi:10.1371/journal.pone.0097136.g002
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higher collagen deposition in the liver of mice treated with
CDAA+CCl4 (Fig. 6C). The CDAA diet alone is able to induce
collagen deposition, even if at lower levels compared to the
CDAA+CCl4 group. More importantly, only low collagen
deposition is observed in mice subjected to CCl4 and treated with
CSAA diet. Similar data were obtained by aSMA Immunohisto-
chemistry, which shows the highest level of myofibroblast
activation in the group of mice treated with CDAA+CCl4 at 6
and 9 months (Fig. 6D).
Treatment with CDAA+CCL4 Induces HCC Development
after 9 Months
No tumor development was observed in mice treated with
CSAA diet up to 9 months, not even when associated to CCl4
injection.
At 6 months of treatment, almost 30% of mice treated with
CDAA and CDAA+CCl4 diets develop at least one nodule of
tumor in the liver, with no statistically significant differences
between the two groups (Fig. 7A–C). Although there are no
differences at 6 months of treatment in the percentage of mice
developing tumors, significant differences are observed in the size
of the tumors (Fig. 7D).
Notably, after 9 months of treatment, all mice from CDAA+
CCl4 group show the presence of at least one tumor nodule, with a
median dimension of 9 mm. On the other hand, CDAA-fed mice
with no CCl4 support show HCC in only 35% of cases with a
significantly lower average diameter (Fig. 7C–D).
Microscopically, cancer areas appear completely free from
collagen deposition (Fig. 7B). Furthermore, Immunohistochemical
evaluation of p-AKT, p-c-Myc and Glypican-3, that are associated
to diagnosis and classification of human HCC, reveals a positive
staining also in our mouse model [17–19]. Specifically, after 9
months of treatment a positive staining for p-AKT and p-c-Myc in
the areas of liver parenchyma that were recognized as HCC, was
evident in the CDAA+CCl4 group, differently from all the other
groups (Fig. 8A). Glypican-3 Immunohistochemistry reveals
positive staining in the tumor nodules, similarly to what happens
in humans, and in the zone 3 of the parenchyma of damaged liver
in the CDAA+CCl4 group [20] (Fig. 8B). In addition to these data,
we did not observe any nuclear staining for b-Catenin (data not
shown).
Changes in Pro-carcinogenic Gene Expression Anticipate
Tumor Formation
In CDAA and CDAA+CCl4 groups we observed a significant
increase in the mRNA expression starting at 3 months of the pro-
carcinogenic genes such as the Insulin-like Growth Factor-2 (IGF-
2) and Osteopontin (SPP-1), respectively involved in angiogenesis
and migration/metastasis (Fig. 8C–D). In the same groups, the
expression of the tumor suppressor gene Phosphatase and Tensin
Figure 3. Gene expression of elements involved in carbohydrate and lipid metabolism. qRT-PCR expression shows a progressive decrease
of the amount of PEPCK (A), G6Pase (B), ChREBP (D), ACOX-1 (E) and CPT1A (F) mRNA expression in the groups of CDAA or CDAA+ CCl4, while only a
slight decrease is observed for mRNA expression of SREBP-1c (C). Data represent mean6 SD; o` p,0.05 vs CSAA 1 month; *p,0.05 vs CSAA 3 months;
1p,0.05 vs CSAA 6 months; #p,0.05 vs CSAA 9 months; c¸ p,0.05 vs CDAA 6 months; u` p,0.05 vs CDAA 9 months.
doi:10.1371/journal.pone.0097136.g003
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Homolog (PTEN) is significantly reduced again starting at 3
months (Fig. 8E). The expression of pro-carcinogenic genes was
associated to a progressive increase in hepatocyte proliferation in
CDAA+CCl4 group as measured by Ki67 labeling that signifi-
cantly increased at 6 months and reached the highest levels at 9
months (3.860.5 labeled parenchymal cell/field vs 2.260.5 in
CDAA-treated animals, p,0.05 and data not shown).
Discussion
In this study, we have provided evidences that CDAA diet
induces peripheral insulin resistance already in the first month
after treatment, and this was associated to the pathological
spectrum of NAFLD, including NASH and HCC. Peripheral
insulin resistance is a primary feature of NAFLD/NASH, and is
probably one of the main co-factors involved in the worsening of
Figure 4. Treatment with CDAA or CDAA+CCl4 induces hepatic inflammation in mice. A) Immunohistochemistry for pan-macrophage
marker F4/80. B) TNFa and (C) MCP-1 mRNA levels are increased in CDAA or CDAA+ CCl4 already after 1 month of treament. D–F) Markers of
Inflammasome activation ASC, Caspase-1 and IL-1b show increased expression in CDAA or CDAA+ CCl4 groups. Data represent mean6 SD; o` p,0.05
vs CSAA 1 month; *p,0.05 vs CSAA 3 months; 1p,0.05 vs CSAA 6 months; #p,0.05 vs CSAA 9 months; c¸ p,0.05 vs CDAA 6 months; u` p,0.05 vs
CDAA 9 months.
doi:10.1371/journal.pone.0097136.g004
HCC and NASH
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the disease [8,21]. Thus the novelty of our results is the
demonstration that the CDAA+CCl4 model determines peripheral
insulin resistance, NAFLD and its progression to HCC. Using this
novel experimental approach we observed: a) development of
peripheral insulin resistance already after 1 month; b) entire
spectrum of lesions ranging from simple steatosis to NASH and
HCC; c) development of HCC after 9 months of treatment in all
mice; d) association of HCC development to increased extracel-
lular matrix deposition; e) significant modification of oncogenic
genes expression already after 3 months of treatment. Thus, this
experimental model is able to guarantee in 9 months the
development of HCC in almost 100% of animals and to early
resemble the main features of the progression from NAFLD to
NASH and HCC.
In the majority of human cases, HCC arises in patients with
advanced chronic liver injury and/or cirrhosis [1]. NAFLD, which
is present in up to 90% of all obese persons and in up to 70% of
persons with type 2 diabetes, is a recognized risk factor for HCC,
that may develop in NASH in the absence of cirrhosis [1].
However, the study of the molecular mechanisms linking steatosis
development to chronic liver injury and HCC is hampered by the
lack of adequate experimental models that often do not resemble
the human situation [22], either are not associated to a significant
development of chronic liver injury or lead to a cachectic
phenotype that does not allow a long period of observation, as
needed for carcinogenesis. In the CDAA model, mice develop
steatosis in the absence of a high fat diet, mice continue to eat, do
not reduce the appetite and the amount of calories introduced and
weight changes are similar to control diet. Furthermore, in
comparison to other existing rodent models, CDAA is able to drive
the progression of steatosis (NAFLD) toward a condition of
inflammation and fibrosis (NASH).
We have investigated the potential mechanisms that could
explain the hepatic steatosis. First of all we demonstrated that
CDAA-treated mice were more insulin resistant (in the periphery)
already at one month as compared to the control CSAA diet-
treated mice. Data in the literature show controversial results
concerning the potential condition of insulin resistance in the
course of CDAA treatment in rodents [23,24], mainly based on
methods that provide only a partial and indirect measurement of
insulin resistance, and related to the fasting glycemic and
insulinemic state [24,25]. Here insulin resistance was measured
by the euglycemic-hyperinsulinemic clamp, which represents the
gold standard for the evaluation of insulin sensitivity [26], and the
results were confirmed by finding increased fasting insulin
concentrations (Figure 1). This condition was even enhanced by
the addition of CCl4 to the diet. The mechanisms by which CDAA
diet induces insulin resistance are unknown but could be related to
Figure 5. Treatment with CDAA or CDAA+CCl4 induces liver injury and expression of markers of hepatic fibrogenesis in mice. A) The
total degree of liver injury (hepatic steatosis and necroinflammation) was determined according to the NAS score. B) The number of apoptotic cells
was measured with TUNEL and expressed as apoptotic cell/field. C–E) qRT-PCR shows a progressive increase, in a time dependent manner, of the
amount of TIMP-1 (C), CTGF (D) and TGFb (E) mRNA expression in the group of CDAA, with the evidence of a promoting effect exerted by CCl4
starting from month 3. Data represent mean6 SD; o` p,0.05 vs CSAA 1 month; *p,0.05 vs CSAA 3 months; 1p,0.05 vs CSAA 6 months;#p,0.05 vs
CSAA 9 months; c¸ p,0.05 vs CDAA 6 months; u` p,0.05 vs CDAA 9 months.
doi:10.1371/journal.pone.0097136.g005
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the gut microbiota metabolism of choline as shown in humans
[27]. Metabolomics data have indicated that reduced concentra-
tions of lysophosphocholine, in particular reduced lyso-PC C18:2,
and lyso-PC C16:0, are associated with peripheral insulin
resistance [28] and hepatic steatosis [29,30] [31]. Moreover, we
found that CDAA diet increases Inflammasome components in the
liver, which supports our hypothesis of a possible link between gut
microbiota modifications, insulin resistance and progression of
liver injury [32,33]. The discovery that CDAA diet induces
peripheral insulin resistance is important for the translation of this
animal model to the human studies. To our knowledge, this is the
first experimental model where a clear link between peripheral
insulin resistance, NASH development and HCC formation has
been established. In human patients with NAFLD/NASH,
peripheral insulin resistance is a primary feature of the disease,
even in lean subjects that do not present the characteristics of
metabolic syndrome [34]. Moreover, a worse peripheral insulin
resistance state has been associated with the presence of fibrosis
[8]. To investigate if CDAA was worsening also hepatic insulin
resistance, we have measured the expression of liver enzymes
associated with glucose production (G6Pase), gluconeogenesis
(PEPCK) and de-novo lipogenesis as SREBP-1c and ChREBP
[16,35]. The results show that G6Pase and PEPCK mRNA
expression was decreased, indicating a parallel decrease in glucose
production. This is in agreement with the observed reduction in
FPG and possibly due to the increase in fasting plasma insulin that
is known to suppress both glucose production and gluconeogenesis
[36]. ChREBP and SREBP-1c expressions were also reduced
indicating that de-novo lipogenesis was not directly implicated in
the development of liver steatosis. On the other hand, the
reduction in ACOX-1 and CPT1A indicates that CDAA diet
reduced hepatic fatty acid oxidation and this could be one of the
mechanisms for hepatic triglyceride deposition and for the higher
lipid deposition in CDAA+CCl4 treated animals, presumably
mediated by TGFb signaling in hepatocytes [12] [37]. Thus, we
can conclude that CDAA induces steatosis mainly by reducing
FFA oxidation, while neither de novo lipogenesis nor glucose
production seem to play an important role.
Despite the intrinsic differences among etiological factors for
HCC, a common denominator at the origin of this neoplasia is the
perpetuation of a wound-healing response triggered by parenchy-
mal cell death, the ensuing inflammatory reaction and the
concomitant fibrosis progression [38]. Indeed, HCC almost always
develops on a background of chronic liver injury including chronic
hepatitis and cirrhosis, conditions referred as preneoplastic stages
[39]. Accumulating evidences indicate that the inflammatory
Figure 6. Treatment with CDAA or CDAA+CCl4 induces hepatic fibrosis in mice. A–B) qRT-PCR expression shows a progressive increase, in a
time dependent manner, of the amount of Collagen a1(I) (A) and aSMA (B) mRNA in the group of CDAA, with the evidence of a promoting effect
exerted by CCl4 starting from month 6. Conversely, mice treated with control diet (CSAA) do not show any time-dependent increase neither in the
level of Collagen a1(I) nor of aSMA, not even after chronic CCl4 injection. C–D) Morphometric analysis shows increased collagen deposition by Sirius
Red staining (C) and increased HSC activation by aSMA Immunohistochemistry (D) in the liver of CDAA treated mice in comparison to CSAA treated
mice. This condition is even enhanced in the liver of mice treated with CDAA+CCl4. Data represent mean6 SD; *p,0.05 vs CSAA;#p,0.05 vs CSAA+
CCl4; o` p,0.05 vs CDAA.
doi:10.1371/journal.pone.0097136.g006
HCC and NASH
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reaction characteristic of chronic liver injury actively participates
in the development of hepatic fibrosis, as well as in the activation
of the potent regenerative response of liver parenchyma, ultimately
leading to HCC development [40,41]. For instance, the produc-
tion of cytokines such as TNFa and IL-6 is essential to trigger
hepatocyte proliferation, liver regeneration and animal survival
after partial hepatectomy [41]. On this regard, in our model we
observed an higher number of infiltrating macrophages (signifi-
cantly increased in CDAA+CCl4-treated mice compared to all
other groups) and this was accompanied by a complete repertoire
of the inflammatory response such as apoptotic cells, TNFa,
MCP-1 and components of the Inflammasome pathway (ASC,
Caspase-1, IL-1b) gene expression. Inflammasomes are intracel-
lular multiprotein complexes expressed in both parenchymal and
non-parenchymal cells of the liver that in response to cellular
danger signals activate Caspase-1 and release the pro-inflamma-
tory cytokine IL-1b, and their role in NASH development is
controversial [42]. In a majority of Inflammasomes, activation of
Caspase-1 requires interaction with the adaptor protein ASC and
this leads to increased IL-1b synthesis and secretion, that finally
synergizes with TNFa to induce cytotoxicity, HSC activation and
maintenance of macrophages in inflammatory state [43]. Thus, it
is possible that the inflammatory milieu occurring in the damaged
liver in our model favors survival of preneoplastic hepatocytes,
promotes the generation of a fibrotic substrate and eventually
contributes to carcinogenesis [44].
As known from the literature, both hepatic steatosis and fibrosis
represent independent risk factors for HCC development [45,46].
In our hands, HCC development was associated to steatosis and
fibrosis in 35% of mice in the CDAA alone-treated group. Recent
studies used CDAA diet in mice: Denda et al. reported a 100%
incidence in preneoplastic foci after 65 weeks of treatment, with no
further information on the presence of lesions at earlier time points
[47]. In the study from Kodama et al. mice fed CDAA diet up to
20 weeks showed steatosis and fibrosis, with no mention on the
development of carcinogetic foci [23]. In our study the addition of
a low-chronic dose of CCl4 to the CDAA administration promoted
HCC development in 100% of mice after 9 months of treatment.
This was associated to increased extracellular matrix deposition.
Thus, CCl4 should be considered as a promoting factor in CDAA
diet-induced liver damage. It could be hypothesized that, even at
low doses, CCl4 synergizes with hepatic steatosis in the develop-
Figure 7. Treatment with CDAA+CCl4 induces development of HCC after 9 months. A) Mice sacrificed after 1 and 3 months from the
beginning of the treatment do not show any nodular lesions in the parenchyma. Conversely, mice sacrificed after 6 months of treatment show few
nodular lesions compatible with HCC. After 9 months of treatment mice show a liver parenchyma completely damaged. B) Histochemical staining for
H&E and Sirius Red show respectively no fat deposition and absence of collagen content into the nodules. C) After 6 months of treatment, about 30%
of mice show HCC development both with CDAA and CDAA+CCl4. After 9 months of treatment, 100% of mice from the CDAA+CCl4 group show at
least one nodule into the liver parenchyma. D) After 6 months, the average of nodules dimension in the group of CDAA mice is significantly lower in
comparison to that of the group of CDAA+CCl4 mice. After 9 months, the average of nodules dimension in the group of CDAA+CCl4 mice results of
9 mm, in comparison to 3 mm of the group of mice treated with CDAA alone. Data represent mean 6 SD; *p,0.05 vs CDAA.
doi:10.1371/journal.pone.0097136.g007
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ment of liver injury and HCC, as shown by increased fibrosis
deposition at 6 months and increased nodules formation at 9
months in CDAA+CCl4-treated mice. On this regard, in our
model we observed higher macrophages infiltration at 3 months in
CDAA+CCl4-treated animals, followed by increased liver injury
(as determined by the NAS score), markers of fibrogenesis (type I
collagen gene expression and HSC activation) and extracellular
matrix deposition starting from 6 months in CDAA+CCl4-treated
mice.
Thus our model shows all the main features of the typical
condition of HCC development, including the early modification
in the expression of pro-carcinogenetic genes, increased hepato-
cyte proliferation and the expression of markers in the tumor
parenchyma, similarly to the human condition. Specifically, both
in the CDAA and CDAA+CCl4 groups increased mRNA levels of
IGF-2 and SPP-1 genes, respectively involved in angiogenesis and
migration/metastasis [48], and decreased mRNA levels of the
oncosoppressor gene PTEN were observed at 3 and 9 months
[49,50], additionally confirming the neoplastic potential of our
model even at early stages. In addition to the current data, several
similarities with the human pattern of HCC have been shown in
our model, by the positive staining for p-AKT, p-c-Myc and
Glypican-3 distribution observed in the tumor parenchyma of
mice treated for 9 months with CDAA and CCl4. Furthermore,
the absence of any nuclear stain for b-Catenin, which is usually
observed in poorly differentiated HCC is consistent with the
histopathological diagnosis of well differentiated HCC in our
mouse model.
In conclusion, our study provides a reproducible model that
recapitulate the pathological spectrum of human NALFD evolving
towards HCC, highlighting the potential role of peripheral vs
hepatic insulin resistance and may therefore represent an ideal tool
to investigate the interaction mechanisms and new potential genes
hypothetically involved in HCC development.
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Figure 8. The expression of pro-carcinogenic genes is modified already after 3 months of treatment. A) Immunohistochemistry for p-
AKT and p-c-Myc shows positive staining in the liver parenchyma of CDAA+CCl4 mice, in correspondence of HCC foci (20X magnification) B) Glypican-
3 Immunohistochemistry shows positive staining in the tumor area (5X and 20X magnification). C) Mice treated with CDAA or CDAA+CCl4 show,
starting at 3 months, increased levels of mRNA for IGF-2 and (D) SPP-1 and (E) decreased mRNA levels of PTEN. Data represent mean 6 SD; *p,0.05
vs CSAA; #p,0.05 vs CSAA+CCl4.
doi:10.1371/journal.pone.0097136.g008
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